Introduction
============

Prostate cancer (PCa) has the highest incidence on a global scale for men, which is the third leading cause of cancer death among men. Between 1990 and 2013, the PCa incidence increased globally by 217%.[@b1-ott-11-3149],[@b2-ott-11-3149] The vast majority of patients in the early stages of PCa may achieve excellent long-term cure rates by radical prostatectomy, some form of radiation therapy, or androgen-deprivation therapy. However, 10%--20% of the patients develop castration-resistant prostate cancer within about 5 years of follow-up, and 30%--50% of men will experience biochemical prostate specific antigen (PSA) recurrence within 10 years after treatment.[@b3-ott-11-3149],[@b4-ott-11-3149] Now, it has been realized that novel powerful biomarkers of PCa for early assessment and effective therapeutic treatment are needed.

Sushi repeat-containing protein X-linked 2 (*SRPX2*) was found in pro-B acute leukemia for the first time in 1999. It was described as a downstream target gene for *E2A-HLF* fusion gene.[@b5-ott-11-3149] The SRPX2 protein consists of 465 amino acid residues, including one DUF4174 domain, three sushi repeat domains, and one hyaline repeat (HYR) domain (GenBank NP-055282). Some of the initial studies have shown that SRPX2 plays a crucial role in the development of the cerebral language center. The mutations of SRPX2 were identified to lead to rolandic seizures, language or cognitive dysfunction, and mental retardation.[@b6-ott-11-3149] In addition to expression in normal tissues in brain, heart, lung, and placenta, high levels of SRPX2 expression have been revealed in various tumor tissues.[@b7-ott-11-3149],[@b8-ott-11-3149] As an extracellular matrix protein, SRPX2 has been shown to be involved in proliferation, migration, adhesion, and invasion of tumor cells through different signaling pathways and promote tumor progress.

In our previous studies, human PCa cell line DU145 was treated with either mtDNA replication reagent ethidium bromide or cell cycle inhibitor flavopiridol for years, and those cells that survived such a long-term treatment were functionally inhibited by mitochondria, and the cells were revealed with typical Warburg and cancer stem cell features. Comparative transcriptomic data from these cells revealed significantly higher levels of SRPX2 compared with their parental control cells,[@b9-ott-11-3149],[@b10-ott-11-3149] indicating a possible role of SRPX2 in PCa. To explore the clinical significance of SRPX2 in this study, we first examined its expression in different PCa cell lines and discovered low level of SRPX2 expression in the LNCaP cell line, compared with its expression in other aggressive PCa cell lines DU145 and PC3. Based on the above findings, we further immunohistochemically examined the expression of SRPX2 in a series of 106 PCa tumors and 10 noncancerous prostate tissue samples. The correlations between SRPX2 protein expression and conventional clinicopathological features were statistically explored, and its survival correlation was analyzed with the Kaplan--Meier method.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by the Institutional Ethics Review Board of Zhengzhou University, Zhengzhou, China. All involved patients agreed to participate in this study and submitted written informed consent at the First Affiliated Hospital of Zhengzhou University.

Cell lines
----------

Three PCa cell lines LNCaP, DU145, and PC3 were purchased from American Type Culture Collection (Manassas, VA, USA) and sustained in our laboratory for the research. The three cell lines were derived from lymph node metastases, brain metastases, and bone metastases in patients with PCa, respectively. Cells were routinely cultured in RPMI-1640 medium (11835-063; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, 10500-064; Thermo Fisher Scientific), 100 U/mL of penicillin, and 100 µg/mL of streptomycin (15140122; Thermo Fisher Scientific) at 37°C in a 5% CO~2~ atmosphere.

RT-PCR
------

Cells in 80% confluence were washed with cold PBS before 1.0 mL Trizol reagent was added to extract total RNA. Then the RNA was precipitated by isopropanol, washed with 75% ethanol, and dissolved using 20 µL 0.1% DEPC. The RNA sample was then reverse transcribed into cDNA by means of the RevertAid First Strand cDNA Synthesis Kit (\#K1622; Thermo Fisher Scientific) according to the manufacturer's instruction. The synthesized cDNA was used for PCR by using FastStart Universal SYBR Green Master (Rox) (04 913 914 001; Hoffman-La Roche Ltd., Basel, Switzerland) on the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific). The primers used for PCR were as follows: forward primer GCTCTCTTTCTGCTGTTCTTCCT; reverse primer TGTATAACACCATCGGGGGAC. The analysis of all samples was repeated at least three times, and the relative quantitative results were analyzed by 2^−ΔΔCt^ values.

Western blotting
----------------

All the cells at 80% confluence were harvested by using cell scraper, and the cells were washed twice with PBS at 4°C. They were then lysed with RIPA buffer (89900; Thermo Fisher Scientific) containing 100 mM PMSF (1862209; Thermo Fisher Scientific) on ice for 30 minutes. Cell lysates were centrifuged at 12,000 *g* for 10 minutes at 4°C, and then total protein concentration was investigated using BCA reagent (Beyotime, Beijing, China). Aliquots of 20 µg proteins mixed with sodium dodecyl sulfate (SDS)-loading buffer were boiled for 10 minutes. The protein samples were subjected to 10% SDS-polyacrylamide gel electrophoresis before electro-transferred onto high-quality polyvinylidene difluoride membranes in a Trans-Blotting apparatus (Bio-Rad Laboratories Inc., Hercules, CA, USA). After blocking with 5% BSA blocking buffer for 1 hour at room temperature, the membranes were incubated at 4°C overnight with mouse antihuman SRPX2 monoclonal (66266-1-Ig; Proteintech, Wuhan, China). The membranes were washed three times with TBST (TBS with 0.1% Tween) and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody diluted 3,000 times with TBST at room temperature for 1 hour. Finally, immunoreactive bands were visualized with an enhanced chemiluminescence detection reagent (Beyotime). The protein bands were normalized to ACTIN and quantified by using Image Lab 2.0 Software (Bio-Rad Laboratories Inc.).

Patients
--------

One hundred and six cases of formalin-fixed and paraffin-embedded PCa specimens were randomly included in this study. All the patients were diagnosed and surgically treated at the First Affiliated Hospital of Zhengzhou University between December 2005 and August 2017. All patients treated with chemotherapy, hormone therapy, or radiotherapy before surgery were excluded from this study. All patients were followed up from the date of confirmed diagnosis until death or August 2017. The clinicopathological information of the 106 PCa patients is summarized in [Table 1](#t1-ott-11-3149){ref-type="table"}. The ages of all patients ranged from 51 to 92 years with a median age of 70.5 years. In accordance with the Gleason score system, there were 34 low- (4--6), 43 moderate- (7), and 29 (8--10) high-grade tumors. The TNM staging following the Would Health Organization (WHO) standard showed 56 stage II patients and 50 stage III and IV patients. All involved specimens were reviewed and diagnosed by at least two pathologists from the First Affiliated Hospital of Zhengzhou University.

Immunohistochemistry (IHC)
--------------------------

The SPlink Detection Kits (Biotin-Streptavidin HRP Detection Systems, SP9000, ZSGB-BIO, Beijing, China), were applied for IHC detection of SRPX2 according to the manufacturer's instruction. Paraffin-embedded PCa tissues were cut into 3 µm sections, dried at 60°C for 2 hours and stored at 4°C. Before IHC, the paraffin sections were deparaffinized and then microwaved in citrate buffer (pH 6.0) for 15 minutes for antigen retrieval. The slides were then allowed to recover to room temperature and washed with PBS. To restrict the activity of endogenous peroxidase and avoid nonspecific staining, the slides were blocked with H~2~O~2~ (3%) and goat serum for 15 minutes at room temperature. They were then incubated with SRPX2 antibody (1:400, ab91584, Abcam, Shanghai, China) at 4°C overnight, followed by incubation with biotin-labeled goat anti-mouse/rabbit immunoglobulin G (IgG) polymer for 15 minutes and HRP for 30 minutes at room temperature. Whereafter, all slides were stained with 3,3′-diaminobenzidine tetrahydrochloride for 3--5 minutes and counterstained with hematoxylin, dehydrated, and mounted. The human lung tissue, always positive for SRPX2 staining, was used as positive control in our study. For negative controls, the primary antibody was replaced with nonimmune rabbit IgG with the same concentration in this study.

Immunohistochemical scoring
---------------------------

The immunostaining of SRPX2 was evaluated by two pathologists from the Department of Pathology of the First Affiliated Hospital of Zhengzhou University with consensus. The evaluators were blinded to the clinical data of patients. The level of SRPX2 expression in PCa samples was assessed by semiquantitative evaluation of immunohistochemical staining, including the assessment of the staining intensity and staining extent of the samples. For the scoring of staining extent, samples without stained cells were rated as 0, those with \<25% stained cells as 1, those with 25%--50% stained cells as 2, and those with \>50% stained cells were rated as 3. The staining intensity was counted as 0, 1, 2, and 3 when the outcomes of staining revealed no positive cells, weak staining, moderate staining, and strong staining, respectively. The results of immunohistochemical staining scores are shown in [Table 2](#t2-ott-11-3149){ref-type="table"}. The samples were grouped as negative for a score of 0 (−), moderately positive for a score of 1--4 (+), and strongly positive for a score of 5--6 (++) according to the final score (the sum of the extent and intensity score).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Data such as SRPX2 expression in mRNA or protein level were analyzed using the Student's *t*-test. Chi-square tests (Pearson's and linear-by-linear, as appropriate) or Fisher's exact probabilities were used for assessment of the associations between SRPX2 expression and clinicopathological characteristics. Survival analysis was performed using the Kaplan--Meier method, and groups were compared with two-sided log-rank tests. Univariate and multivariate survival analyses were accomplished using Cox proportional regression hazard model to identify the significant factors that were involved in prognosis. For all the analyses, *P*\<0.05 was considered to be significant.

Results
=======

SRPX2 expression in PCa cell lines
----------------------------------

Variable SRPX2 expression could be detected in the human PCa cell lines LNCaP, DU145, and PC3. However, compared to those in the aggressive DU145 and PC3 cell lines, significantly lower levels of SRPX2 expression were verified in the LNCaP cell line with both RT-PCR in mRNA and Western blotting in protein levels ([Figure 1](#f1-ott-11-3149){ref-type="fig"}).

SRPX2 expression in PCa tissues
-------------------------------

There were 106 cases of PCa specimens and 10 noncancerous prostate tissues adjacent to tumor that were detected by immunohistochemical staining to clarify the SRPX2 expression in this study. It turned out that SRPX2 protein was significantly overexpressed in PCa tissues. The typical cytoplasmic staining of SRPX2 protein in PCa cells is shown in [Figure 2](#f2-ott-11-3149){ref-type="fig"}. Of the total 106 samples, 69 (65.10%) cases were strongly positive, 30 (28.30%) were moderately positive, while only seven (6.60%) were negative for SRPX2 expression. However, the noncancerous prostate tissues were all negative for SRPX2 expression.

Correlations between SRPX2 expression and clinicopathological features
----------------------------------------------------------------------

As summarized in [Table 3](#t3-ott-11-3149){ref-type="table"}, the correlations of SRPX2 protein expression with the clinicopatological features were analyzed by chi-square test or Fisher's exact test. Results indicated that SRPX2 protein expression was positively correlated with Gleason score (*P*=0.008). In addition, it was also found that the SRPX2 protein expression in PCa samples was positively associated with lymph node metastasis (*P*=0.009) and distant metastasis (*P*=0.021). No significant association between age (*P*=0.952), PSA (*P*=0.124), and Union for International Cancer Control (UICC) stage (*P*=0.117) of patients, and SRPX2 protein expression was discovered in this study.

Increased SRPX2 expression is significantly associated with unfavorable survival in PCa
---------------------------------------------------------------------------------------

The overall survival (OS) rate of the 106 PCa patients was 37.7%. A total of 66 deaths were observed in the 106 patients during the follow-up period. The follow-up time ranged from 2 to 147 months with a median follow-up time of 58 months. Of all the patients, seven cases of negative SRPX2 expression were observed, while 30 and 69 cases were moderately and strongly positive for the protein expression. As shown in [Figure 3](#f3-ott-11-3149){ref-type="fig"}, Kaplan--Meier survival curve and log-rank test proved that high SRPX2 protein expression in PCa was significantly correlated with poor OS of patients (*P*\<0.001). The survival rates of patients with SRPX2 negative, moderate, and strong expressions were 71.42%, 66.67%, and 21.74%, respectively.

SRPX2 expression in PCa is an independent risk factor for OS
------------------------------------------------------------

Univariate and multivariate analyses were performed using Cox proportional hazards regression method on the basis of the above clinicopathological parameters and the expression of SRPX2 in tumor cells. As shown in [Table 4](#t4-ott-11-3149){ref-type="table"}, Gleason score (hazard ratio \[HR\] =1.314, 95% confidence interval \[CI\]: 1.043--1.657, *P*=0.021), UICC stage (HR =1.425, 95% CI: 1.021--1.990, *P*=0.037), and SRPX2 expression (HR =1.461, 95% CI: 1.118--1.909, *P*=0.006) were identified as independent risk factors for shorter OS in the PCa patients.

Discussion
==========

PCa is a highly heterogeneous disease. The main clinical treatments of PCa include radical prostatectomy, radiation therapy, chemotherapy, and androgen ablation. In recent years, the diagnosis and therapy of this disease have been greatly improved, but challenges remain in regard to relapse and castration resistance after receiving treatment. On account of the Western lifestyle and the changing in dietary pattern at present, the incidence of PCa in China has increased steadily.[@b11-ott-11-3149] The prognostic evaluation of patients with PCa is still largely dependent on Gleason score, level of PSA, surgical margin status, lymph node metastases, and TNM staging.[@b12-ott-11-3149]--[@b14-ott-11-3149] Specific molecular markers as prognostic indicators for PCa are still missing.

SRPX2 is a novel chondroitin sulfate proteoglycan,[@b7-ott-11-3149] which has been shown to participate in a series of biological processes of tumor cells. SRPX2 enhances the migration and adhesion of gastric cancer cells directly or indirectly by increasing the phosphorylation levels of focal adhesion kinase (FAK).[@b15-ott-11-3149] Similarly, SRPX2 promotes the migration and invasion of pancreatic ductal adenocarcinoma cells through FAK pathway.[@b16-ott-11-3149] In addition, studies have shown that silencing SRPX2 in colon cancer HCT116 cells remarkably impairs the proliferation, adhesion, migration, and invasion of cancer cells. On the contrary, elevated expression of SRPX2 in SW480 cells promotes cell migration and invasion. Besides, downregulation of SRPX2 protein resulted in a significant downregulation of β-catenin, MMP2/9, suggesting that SRPX2 may promote the invasion of colorectal cancer by regulating MMP2/9 expression through Wnt/β-catenin signaling pathway.[@b17-ott-11-3149]

Several previous studies have reported that SRPX2 is highly expressed in various malignant tumor tissues, such as gastric cancer,[@b18-ott-11-3149] colorectal cancer,[@b17-ott-11-3149] pancreatic cancer,[@b16-ott-11-3149] and glioblastoma.[@b19-ott-11-3149] Overexpression of SRPX2 is significantly associated with unfavorable outcomes in these patients. In agreement with the above studies, we first noticed the upregulation of SRXP2 in the PCa stem-like cells in our laboratory.[@b9-ott-11-3149],[@b10-ott-11-3149] Further study of the PCa cell lines LNCaP, DU145, and PC3 verified significantly higher levels of SRPX2 expression in those aggressive cell lines DU145 and PC3, while the biological rather mild cell line LNCaP expressed significantly lower levels of SRPX2, in both mRNA and protein levels.

Therefore, we further examined the expression of SRPX2 in a series of 106 cases of formalin-fixed and paraffin-embedded PCa tissues in the present study. Immunohistochemical staining showed that SRPX2 was highly expressed in PCa with a positive rate of 93.40%. We next investigated the relationship between SRPX2 expression and clinicopathological features in PCa. In the present study, high levels of SRPX2 protein expression in the 106 PCa samples were significantly correlated with the high Gleason score, lymph node metastasis, and distant metastasis. Accordingly, we considered that the overexpression of SRPX2 might contribute to the development and progression of PCa. Indeed, further survival analyses revealed that high levels of SRPX2 protein expression in PCa were significantly associated with shorter OS, indicating a poor prognostic factor of SRPX2 in PCa. Univariate and multivariate Cox proportional hazards regression analyses showed that SRPX2 expression was a significantly independent predictor of prognosis in PCa patients. Thus, our results merit extensive SRPX2 studies in terms of its function, predictive and prognostic values in PCa.

As mentioned above, SRPX2 plays an important role in the adhesion, migration, and invasion of various tumor cells. Existing in a variety of proteins with different functions, the CCP domains of SRPX2 protein influence the cell adhesion by mediating specific protein--protein and protein--carbohydrate interactions.[@b8-ott-11-3149],[@b20-ott-11-3149] The HYR domain plays a role in cell adhesion process.[@b21-ott-11-3149] Schwanzer-Pfeiffer et al have suggested that SRPX2 may influence cell adhesion by regulating ICAM1, E-selectin shedding and the expression of membrane bound adhesion molecules.[@b22-ott-11-3149] The results of phylogenetic analysis suggested that SRPX2 and selectin families are highly homologous and belong to the same gene family emerged during vertebrate evolution.[@b23-ott-11-3149] It has been reported that selectin promotes the interaction between tumor cells and endothelial cells, which leads to tumor progression and metastasis.[@b24-ott-11-3149],[@b25-ott-11-3149] Besides, selectin is conducive to promoting angiogenesis.[@b26-ott-11-3149],[@b27-ott-11-3149] As an extracellular matrix protein,[@b28-ott-11-3149] SRPX2 is involved in the regulation of extracellular matrix protein remodeling through its proteolytic activity. Royer-Zemmour et al demonstrated that SRPX2 is a ligand for urokinase-type plasminogen activator receptor and interacted with CTSB and ADAMTS4,[@b29-ott-11-3149] both of which belong to the important components of extracellular proteolysis machinery. CTSB is an activator of uPA. Moreover, it has been found that SRPX2 is overexpressed in HUVEC.[@b15-ott-11-3149] SRPX2 interacts with uPAR in endothelial remodeling during the early phases of angiogenesis.[@b24-ott-11-3149] These studies suggest that SRPX2 protein is conducive to promote angiogenesis. Recently, Raza and Jaiswal constructed a PCa-specific gene regulatory network using novel simple statistics based on an approach extracting differentially expressed genes and found regulatory relationships among the genes in PCa. The results indicate a potential link between *EMP1*, *CSTF1*, and *SRPX2* genes in PCa and predict the role of SRPX2 as target for PCa.[@b30-ott-11-3149]

Conclusion
==========

The current study reveals significantly higher levels of SRPX2 expression in aggressive PCa cell lines, and overexpression of SRPX2 protein in PCa predicts unfavorable clinicopathological features and poor outcome of patients. Consequently, it may be used as a novel prognostic marker and a potential target for PCa treatment. It should be noted that the present study has explored only a limited number of PCa samples, and the crucial roles of SRPX2 in PCa and the relevant molecular mechanisms deserve to be further elucidated.
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![RT-PCR and Western blotting of SRPX2 expression in PCa cell lines.\
**Notes: A** and **B** show a representative SRPX2 RT-PCR result and its corresponding histograms, respectively. **C** and **D** show a representative Western blotting of SRPX2 and its corresponding histograms, respectively. \*\**P*\<0.01, \*\*\**P*\<0.001.\
**Abbreviations:** SRPX2, sushi repeat-containing protein X-linked 2; PCa, prostrate cancer.](ott-11-3149Fig1){#f1-ott-11-3149}

![Immunohistochemical staining of SRPX2 in PCa samples.\
**Notes:** The typical diffuse SRPX2 cytoplasmic staining can be found in PCa cells. **A** and **B** show strong SRPX2 positivity; **C** and **D** show moderate SRPX2 positivity; **E** and **F** show SRPX2 negativity (magnification in the left panel: 200×, magnification in the right panel: 400×).\
**Abbreviations:** SRPX2, sushi repeat-containing protein X-linked 2; PCa, prostrate cancer.](ott-11-3149Fig2){#f2-ott-11-3149}

![Kaplan--Meier survival plot.\
**Notes:** High levels of SRPX2 protein expression is significantly associated with a shorter overall survival in PCa (*P*\<0.001).\
**Abbreviations:** SRPX2, sushi repeat-containing protein X-linked 2; PCa, prostrate cancer.](ott-11-3149Fig3){#f3-ott-11-3149}

###### 

Clinical and pathological characteristics for 106 patients with malignant prostate cancer

  Variable           Median (range) or no of patients
  ------------------ ----------------------------------
  Age                70.50 years (51--92)
  Preoperative PSA   60.98 ng/mL (0.10--100.00)
  Follow-up          58.00 months (2--147)
  Gleason score      
   \<7               34
   7                 43
   \>7               29
  UICC stage         
   pT2               79
   pT3--pT4          27

**Abbreviations:** PSA, prostate-specific antigen; UICC, Union for International Cancer Control.

###### 

The criteria of Allred scoring system used for evaluating SRPX2 expression in malignant prostate cancer in our study

  ----------------------------------------------- ---------- ------- ---------- --------------------------------------
  1\. The criteria of intensity scoring system                                  

   Intensity score                                0          1       2          3

   Staining intensity                             Negative   Weak    Moderate   Strikingly positive at low magnitude

  2\. The criteria of percentage scoring system                                 

   Percentage score                               0          1       2          3

   Stained cells (%)                              0          \<25    25--50     \>50

   Total score                                    0\         1--4\   5--6\      
                                                  (−)        (+)     (++)       
  ----------------------------------------------- ---------- ------- ---------- --------------------------------------

**Notes:** The total score was obtained by adding the percentage score to the intensity score. It ranges from 0 to 6.

###### 

The associations of SRPX2 expression levels and the clinicopathological characteristics in prostate cancer

  Clinicopathological variable   Total N   SRPX2 expression   *P*-value[^a^](#tfn3-ott-11-3149){ref-type="table-fn"}                 
  ------------------------------ --------- ------------------ -------------------------------------------------------- ------------- ----------------------------------------------------
  Age (years)                    106       7 (6.60%)          30 (28.30%)                                              69 (65.10%)   0.952[^b^](#tfn4-ott-11-3149){ref-type="table-fn"}
   \<65                          24        1 (4.17%)          6 (25.00%)                                               17 (70.83%)   
   65--75                        47        4 (8.51%)          13 (27.66%)                                              30 (63.83%)   
   \>75                          35        2 (5.71%)          11 (31.43%)                                              22 (62.86%)   
  Gleason score                                                                                                                      0.008[^b^](#tfn4-ott-11-3149){ref-type="table-fn"}
   \<7                           34        3 (8.82%)          16 (47.06%)                                              15 (44.12%)   
   7                             43        3 (6.98%)          11 (25.58%)                                              29 (67.44%)   
   \>7                           29        1 (3.45%)          3 (10.34%)                                               25 (86.21%)   
  PSA (ng/mL)                                                                                                                        0.124[^b^](#tfn4-ott-11-3149){ref-type="table-fn"}
   ≤10                           16        2 (12.50%)         7 (43.75%)                                               7 (43.75%)    
   \>10 and ≤20                  10        1 (10.00%)         4 (40.00%)                                               5 (50.00%)    
   \>20                          80        4 (5.00%)          19 (23.75%)                                              57 (71.25%)   
  UICC stage                                                                                                                         0.117
   pT2                           79        6 (7.60%)          26 (32.91%)                                              47 (59.49%)   
   pT3--pT4                      27        1 (3.70%)          4 (14.82%)                                               22 (81.48%)   
  Lymph node metastasis                                                                                                              0.009[^b^](#tfn4-ott-11-3149){ref-type="table-fn"}
   Negative                      90        6 (6.67%)          30 (33.33%)                                              54 (60.00%)   
   Positive                      16        1 (6.25%)          0                                                        15 (93.75%)   
  Distant metastasis                                                                                                                 0.021
   Negative                      77        6 (7.79%)          27 (35.07%)                                              44 (57.14%)   
   Positive                      29        1 (3.45%)          3 (10.34%)                                               25 (86.21%)   

**Notes:**

Pearson chi-square test;

Fisher's exact probabilities test.

###### 

Univariate and multivariate analysis for overall survival using Cox relative risk

  Variable                                     Univariate analysis    Multivariate analysis                          
  -------------------------------------------- ---------------------- ----------------------- ---------------------- -------
  **SRPX2 expression in tumor**                1.596 (1.246--2.046)   \<0.001                 1.461 (1.118--1.909)   0.006
  **Age**                                      1.024                  0.100                   1.045                  0.005
  (\<65 years vs 65--75 years vs \>75 years)   (0.995--1.053)                                 (1.013--1.079)         
  **Gleason score**                            1.460                  \<0.001                 1.314                  0.021
  (\<7, 7, \>7)                                (1.195--1.782)                                 (1.043--1.657)         
  **PSA (ng/mL)**                              1.005                  0.091                   0.998                  0.568
  (≤10, \>10, and ≤20)                         (0.999--1.012)                                 (0.990--1.005)         
  **UICC stage**                               1.401                  0.028                   1.425                  0.037
  (pT2 vs pT3--pT4)                            (1.037--1.892)                                 (1.021--1.990)         
  **Lymph node metastasis**                    1.311                  0.413                   0.687                  0.315
  (positive vs negative)                       (0.685--2.506)                                 (0.330--1.429)         
  **Distant mestastasis**                      2.070                  0.004                   1.624                  0.099
  (positive vs negative)                       (1.257--3.410)                                 (0.913--2.891)         

**Note:**

Cox regression.

**Abbreviations:** HR, hazard ratio; 95% CI, 95% confidence interval.
